Live Webinar – Start and Stay in Obesity Care: The lmportance of Treatment Maintenance

Mounjaro® (tirzepatide)

I: Type 2 diabetes mellitus: Mounjaro is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is contraindicated or not tolerated; in combination with other drugs that lower blood glucose.

Chronic weight management: Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² to < 30kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes or type 2 diabetes mellitus). See the “clinical Efficacy” section for study results in adults with obstructive sleep apnea and obesity.

P/A: The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose is increased to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. The maximum dose is 15 mg once weekly. The dose can be administered at any time of day, with or without meals. Inject Mounjaro subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.

CI: Hypersensitivity to the active substance or to any of the excipients.

W/P: Patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) have not been studied in clinical trials with tirzepatide. Tirzepatide has not been studied in patients with a history of pancreatitis and should be used with caution in these patients. Patients receiving tirzepatide in combination with a sulphonyl urea or insulin may have an increased risk of hypoglycemia. Tirzepatide has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which could lead to a deterioration in renal function including acute renal failure. Tirzepatide delays gastric emptying. Pulmonary aspiration has been reported in patients receiving long acting GLP-1 receptor agonists undergoing general anaesthesia or deep sedation. This should be considered prior to such procedures. Events of severe gastroparesis and malnutrition have been reported. In patients with non-proliferative diabetic retinopathy requiring acute therapy, and in patients with proliferative diabetic retinopathy or diabetic macular edema, Tirzepatide should be used with caution and appropriate related monitoring. Suicidal behavior, ideation and worsening of depression were reported.
Mounjaro KwikPen contains 5.4 mg benzyl alcohol per dose unit. Large quantities bear risk of accumulation and toxicity („metabolic acidosis“).

IA: Tirzepatide delays gastric emptying, as assessed by paracetamol pharmacokinetics and thereby has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. The use of tirzepatide can reduce the efficacy of oral hormonal contraceptives.

Pr/L: Should not be used during pregnancy. A decision must be made whether to discontinue breast-feeding or to discontinue tirzepatide therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Tirzepatide should not be used for weight reduction during pregnancy.

ADR: Very common and common: Nausea, diarrhea, hypoglycemia, dizziness, hypotension, hypersensitivity reactions (occasionally severe, e.g. urticaria, eczema), abdominal pain, vomiting, dyspepsia, constipation, meteorism, eructation, flatulence, gastroesophageal reflux disease, decreased appetite, hair loss, fatigue, injection site reactions. Uncommon: Delayed gastric emptying, dysesthesia, dysgeusia, cholelithiasis, cholecystitis. Rare: Anaphylactic reaction and angioedema. 

P: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg 4 pre-filled single-dose pens, Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg 1 single-use vial, Mounjaro KwikPen 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg und 15 mg 1 pre-filled multiple-dose pen. Dispensing category B. Consult www.swissmedicinfo.ch for further information.  Eli Lilly (Suisse) SA, Ch. des Coquelicots 16, CP 580, 1214 Vernier (GE). V10-2025

▼ This medicine is subject to additional monitoring. For more information, refer to the professional information / patient information of Mounjaro^® available at swissmedicinfo.ch.